GRI Bio, Inc. (GRI)
| Market Cap | 2.96M -8.9% |
| Revenue (ttm) | n/a |
| Net Income | -9.66M |
| EPS | -11.56 |
| Shares Out | 1.77M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 106,486 |
| Open | 1.820 |
| Previous Close | 1.770 |
| Day's Range | 1.660 - 1.820 |
| 52-Week Range | 1.360 - 80.360 |
| Beta | -0.66 |
| Analysts | Strong Buy |
| Price Target | 21.00 (+1,157.49%) |
| Earnings Date | Aug 20, 2026 |
About GRI
GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company’s portfolio also includes GRI-0803, a novel oral agonist of type 2 Natural Killer T cells ... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for GRI stock is "Strong Buy." The 12-month stock price target is $21.0, which is an increase of 1,157.49% from the latest price.
News
GRI Bio Quarterly report: Q2 2026
GRI Bio has published its Q2 2026 quarterly earnings report on August 14, 2026.
GRI Bio announces U.S. FDA granted ODD to GRI-0621
GRI Bio (GRI) announced that the U.S. Food and Drug Administration, FDA, has granted Orphan Drug Designation, ODD, to GRI-0621 for the treatment of Idiopathic Pulmonary Fibrosis, a progressive, irreve...
GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis
Designation highlights significant regulatory milestone and provides a potential pathway to seven years of U.S. market exclusivity
GRI Bio granted FDA orphan designation for tazarotene
GRI Bio’s (GRI) tazarotene was granted FDA orphan designation as a treatment of idiopathic pulmonary fibrosis, according to a post to the agency’s website.
GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase
Live webcast fireside chat with Marc Hertz, PhD, Chief Executive Officer, on Wednesday, May 20, 2026 Register for the event here LA JOLLA, CA, May 18, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: G...
GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline
Phase 2a data show zero cough and 60% lower treatment-related diarrhea than placebo despite higher nintedanib use in the active arm – suggesting GRI-0621 may mitigate nintedanib-related GI-toxicities ...
GRI Bio Quarterly report: Q1 2026
GRI Bio has published its Q1 2026 quarterly earnings report on May 13, 2026.
GRI Bio Earnings release: Q1 2026
GRI Bio released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
GRI Bio receives UAE patent allowance for inflammatory disease treatments
GRI Bio (GRI) announced it has received a Notice of Allowance from the United Arab Emirates Patent Office for a patent application covering novel type 2 diverse NKT cell agonists…
GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions
Issued claims further strengthen global intellectual property portfolio supporting immune cell modulation platform and expand strategic presence in a high-growth international market
GRI Bio Slides: Corporate presentation
GRI Bio has posted slides in relation to its latest quarterly earnings report, which was published on March 6, 2026.
GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment
Access the “What This Means” segment here
GRI Bio Transcript: Corporate Connect Webinar Series
GRI Bio highlighted positive phase 2A results for its lead IPF program, showing safety, biomarker improvements, and potential disease-modifying effects. Plans include advancing to phase 2B and filing an IND for a lupus program, with ongoing partnership discussions.
GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial
– Live video webcast on Wednesday, February 11 th at 1:00 PM EST
GRI Bio sees cash runway into 1Q27
As of December 31, 2025, the Company had cash and cash equivalents of approximately $8.2M. Following the close of the quarter, the Company raised an additional $6.5M in gross proceeds…
GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026
GRI Bio Earnings release: Q4 2025
GRI Bio released its Q4 2025 earnings on February 4, 2026, summarizing the period's financial results.
GRI Bio Annual report: Q4 2025
GRI Bio has published its Q4 2025 annual report on February 4, 2026.
GRI Bio Registration statement: Registration Filing
GRI Bio filed a registration statement on January 30, 2026, providing details about a securities offering with the SEC.
GRI Bio files $250M mixed securities shelf
06:07 EST GRI Bio (GRI) files $250M mixed securities shelf
GRI Bio Inc trading halted, volatility trading pause
09:32 EST GRI Bio (GRI) Inc trading halted, volatility trading pause
GRI Bio delivers additional data from Phase 2a study of GRI-0621
GRI Bio (GRI) announced additional “positive” data from its recently completed Phase 2a clinical study of GRI-0621 in Idiopathic Pulmonary Fibrosis, IPF, further strengthening potential clinical proof...
GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF
Multiple Independent Molecular Signals Converge to Validate GRI-0621 as a Potential Disease-Modifying Therapy LA JOLLA, CA, Jan. 28, 2026 (GLOBE NEWSWIRE) -- GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or ...
GRI Bio secures U.S. composition of matter patent
GRI Bio (GRI) announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 12,528,775, providing robust new intellectual property protection for novel compound compositions central t...